In the case of Dussiaume v Sandoz Canada Inc. dated May 11, 2023, the plaintiff, Mr. Gary Dussiaume, filed a proposed class action against various defendants, including manufacturers and retailers of the heartburn medication Ranitidine (commonly known as Zantac), such as GlaxoSmithKline Inc., Sandoz Canada Inc., Apotex Inc., Pro Doc Limitée, Sanis Health Inc., Sivem Pharmaceuticals ULC, Teva Canada Limited, Sanofi Consumer Health Inc., 115013 Canada Inc., Laboratoire Riva Inc., Pharmascience Inc., Vita Health Products Inc., and Ranbaxy Pharmaceuticals Canada Inc. The plaintiff alleged that Ranitidine transformed into N-Nitrosodimethylamine (NDMA), a potential carcinogen, and posed health risks to consumers. The plaintiff sought damages for negligence, failure to warn, battery, and other claims on behalf of the proposed class members. The defendants applied to have certain portions of the plaintiff's claims struck or dismissed. They argued that the claims related to an alleged increased risk of harm, mental distress, and medical monitoring had no genuine issues for trial and should be dismissed. The court held that there was no viable cause of action on the negligence and damages claims. As a result, the plaintiff's application for certification was denied. No specific information regarding a financial award had been provided in the case.